Pilot Clinical Trial of Type 1 Dendritic Cells Loaded with Autologous Tumor Lysates Combined with GM-CSF, Pegylated IFN, and Cyclophosphamide for Metastatic Cancer Patients
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Twenty-four patients with metastatic cancer received two cycles of four daily immunizations with monocyte-derived dendritic cells (DC). DC were incubated with preheated autologous tumor lysate and subsequently with IFN-α, TNF-α, and polyinosinic:polycytidylic acid to attain type 1 maturation. One DC dose was delivered intranodally, under ultrasound control, and the rest intradermally in the opposite thigh. Cyclophosphamide (day −7), GM-CSF (days 1–4), and pegIFN alpha-2a (days 1 and 8) completed each treatment cycle. Pretreatment with cyclophosphamide decreased regulatory T cells to levels observed in healthy subjects both in terms of percentage and in absolute counts in peripheral blood. Treatment induced sustained elevations of IL-12 in serum that correlated with the output of IL-12p70 from cultured DC from each individual. NK activity in peripheral blood was increased and also correlated with the serum concentration of IL-12p70 in each patient. Circulating endothelial cells decreased in 17 of 18 patients, and circulating tumor cells markedly dropped in 6 of 19 cases. IFN-γ–ELISPOT responses to DC plus tumor lysate were observed in 4 of 11 evaluated cases. Tracing DC migration with [111In] scintigraphy showed that intranodal injections reached deeper lymphatic chains in 61% of patients, whereas with intradermal injections a small fraction of injected DC was almost constantly shown to reach draining inguinal lymph nodes. Five patients experienced disease stabilization, but no objective responses were documented. This combinatorial immunotherapy strategy is safe and feasible, and its immunobiological effects suggest potential activity in patients with minimal residual disease. A randomized trial exploring this hypothesis is currently ongoing.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells
Nestle, F. O., Alijagic, S., Gilliet, M., Sun, Y., Grabbe, S., Dummer, R., Burg, G., & Schadendorf, D. (1998) · Nature Medicine · doi:10.1038/nm0398-328 · Cited by 2,862 · cited 1×
“material obtained from autologous tumor cells (20).”
Innate or adaptive immunity? The example of natural killer cells
Vivier, E., Raulet, D. H., Moretta, A., Caligiuri, M. A., Zitvogel, L., Lanier, L. L., Yokoyama, W. M., & Ugolini, S. (2011) · Science · doi:10.1126/science.1198687 · Cited by 2,824
Vaccination of patients with B–cell lymphoma using autologous antigen–pulsed dendritic cells
Hsu, F. J., Benike, C., Fagnoni, F., Liles, T. M., Czerwinski, D., Taidi, B., Engleman, E. G., & Levy, R. (1996) · Nature Medicine · doi:10.1038/nm0196-52 · Cited by 1,804 · cited 1×
“DC can be artificially manipulated to present tumor Ags either in the form of defined protein sequences (18, 19) or as antigenic”
BackgroundBlockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity
Curiel, T. J., Wei, S., Dong, H., Alvarez, X., Cheng, P., Mottram, P., Krzysiek, R., Knutson, K. L., Daniel, B., Zimmermann, M. C., et al. (2003) · Nature Medicine · doi:10.1038/nm863 · Cited by 1,314 · cited 1×
“Even though costimulatory molecules and CCR7 are brightly expressed by the injected DC, B7-H1 (PD-L1) expression on their surface might mediate dangerous immunosuppressive mechanisms (61, 62).”
Background
Cited by
Chemoimmunotherapy: Reengineering Tumor Immunity
Chen, G., & Emens, L. A. (2013) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-012-1388-0 · Cited by 242
Personalized Dendritic Cell Vaccines‐Recent Breakthroughs and Encouraging Clinical Results
Mastelic-Gavillet, B., Balint, K., Boudousquie, C., Gannon, P. O., & Kandalaft, L. E. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00766 · Cited by 189
Type I interferons and dendritic cells in cancer immunotherapy
(2019) · International Review of Cell and Molecular Biology · doi:10.1016/bs.ircmb.2019.06.001 · Cited by 124
Colorectal Cancer Immunotherapy: State of the Art and Future Directions
Cornista, A. M., Giolito, M. V., Baker, K., Hazime, H., Dufait, I., Datta, J., Khumukcham, S. S., De Ridder, M., Roper, J., Abreu, M. T., et al. (2023) · Gastro Hep Advances · doi:10.1016/j.gastha.2023.09.007 · Cited by 39
Metadata
- Authors
- Alfaro, C., Perez-Gracia, J. L., Suarez, N., Rodriguez, J., Fernandez de Sanmamed, M., Sangro, B., Martin-Algarra, S., Calvo, A., Redrado, M., Agliano, A., Gonzalez, A., Rodriguez, I., Bolaños, E., Hervás-Stubbs, S., Perez-Calvo, J., Benito, A., Peñuelas, I., Vigil, C., Richter, J., Martinez-Forero, I., & Melero, I.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-12-01
- Volume
- 187
- Issue
- 11
- Pages
- 6130-6142
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2106318553
- Cited by
- 60
- References
- 4
- FWCI
- 3.68
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pilot Clinical Trial of Type 1 Dendritic Cells Loaded with Autologous Tumor Lysates Combined with GM-CSF, Pegylated IFN, and Cyclophosphamide for Metastatic Cancer Patients. https://app.cochat.ai/papers/10.4049/jimmunol.1102209
- The paper
- Alfaro, C., Perez-Gracia, J. L., Suarez, N., Rodriguez, J., Fernandez de Sanmamed, M., Sangro, B., Martin-Algarra, S., Calvo, A., Redrado, M., Agliano, A., Gonzalez, A., Rodriguez, I., Bolaños, E., Hervás-Stubbs, S., Perez-Calvo, J., Benito, A., Peñuelas, I., Vigil, C., Richter, J., . . . Melero, I. (2011). Pilot Clinical Trial of Type 1 Dendritic Cells Loaded with Autologous Tumor Lysates Combined with GM-CSF, Pegylated IFN, and Cyclophosphamide for Metastatic Cancer Patients. The Journal of Immunology. https://doi.org/10.4049/jimmunol.1102209
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.